Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<ul><li><keyword id="6358826" type="LOCATION" weightage="20" keywordseo="Russia">Russia</keyword> has received pre-orders of a billion doses for their <keyword id="1754604" type="PERSON" weightage="20" keywordseo="coronavirus">coronavirus</keyword> vaccine from 20 countries. </li><li>The development came as Russian President Vladimir <keyword id="6355086" type="UNKNOWN" weightage="20" keywordseo="Putin">Putin</keyword>, earlier on August 11, announced that his country has developed the first vaccine that works quite effectively" </li><li>He said that one of his daughters took part in the experiment and she was vaccinated against the coronavirus. </li></ul>Russian Health Minister Mikhail Murashko claims that 20 countries have pre-ordered a billion doses of their new coronavirus vaccine, <a href="https://twitter.com/AFP/status/1293136282823143425">reported AFP. </a> The Russian Direct Investment Fund (RDIF) is investing in the production and promotion of the vaccine abroad The development came as Russian President Vladimir Putin, earlier on August 11, <a href="https://www.businessinsider.in/science/health/news/putin-announced-that-russia-approved-a-covid-19-vaccine-and-gave-it-to-his-daughter-despite-serious-concerns-over-its-safety/articleshow/77482429.cms">announced that his country has developed the first vaccine </a>that works quite effectively" and "forms a stable immunity" against <keyword id="8763838" type="UNKNOWN" weightage="20" keywordseo="covid-19">COVID-19</keyword>. He further disclosed that one of his daughters has already been vaccinated. The vaccine was developed jointly by the Gamaleya Research Institute and the Russian Defence Ministry. It has two separately-injected components that together are expected to build long-term immunity against the virus. The Russian vaccine against the coronavirus will begin production at two sites - the Gamaleya Research Institute and the company Binnopharm. Putin made the claim during a government meeting where he described it as "a very important step for the world". Putin thanked everyone who worked on the first-ever vaccine against the coronavirus and hoped that Russia will be able to start mass production of this medication in the near future. "I hope that our colleagues abroad will also move forward, and there will be quite a lot of products that can be used on the market, on the world market for medicines and vaccines," Putin was quoted as saying by the agency. Clinical trials of the vaccine kicked off on June 18 and included 38 volunteers. All of the participants developed an immunity. The first group was discharged on July 15, the second group on July 20. According to the tally kept by Johns Hopkins University, coronavirus has infected more than 20 million people worldwide. There are six <keyword id="8904563" type="UNKNOWN" weightage="20" keywordseo="covid-19-vaccine">Covid-19 vaccine</keyword> candidates that have reached the Phase 3 level according to the WHO — three are from China and the other three include the ones developed by the University of Oxford and AstraZeneca, Moderna, and one jointly developed by Pfizer and BioNTech. SEE ALSO: <a href="https://www.businessinsider.in/politics/world/news/trump-was-rushed-from-the-briefing-room-by-secret-service-after-a-shooting-outside-of-the-white-house/articleshow/77474005.cms">Trump was rushed from the briefing room by Secret Service after a shooting outside the White House</a> <a href="https://www.businessinsider.in/careers/news/mckinsey-facebook-amazon-nokia-and-some-other-companies-looking-for-a-product-manager-right-now/slidelist/77464438.cms">McKinsey, Facebook, Amazon, Nokia — and some other companies looking for a product manager right now</a> <a href="https://www.businessinsider.in/business/startups/news/how-karan-bajaj-sold-his-less-than-18-month-old-startup-white-hat-jr-to-byjus/articleshow/77415329.cms">A WhatsApp message, six weeks of talks and a $300 million deal – how Karan Bajaj sold his less than 18-month old startup White Hat Jr to Byju’s</a>

Russia claims its new COVID-19 vaccine has pre-orders from 20 countries

<ul class="summary-list"><li>Future <keyword id="11893994" type="UNKNOWN" weightage="60" keywordseo="covid-19" source="Orion">COVID-19</keyword> variants could evade current vaccines and boosters, the CEO of <keyword id="11930683" type="UNKNOWN" weightage="60" keywordseo="biontech" source="Orion">BioNTech</keyword> told the FT.</li><li>We may therefore need new COVID-19 vaccines my mid-2022, Ugur Sahin said.</li><li>BioNTech and Pfizer codeveloped the US' only fully approved COVID-19 <keyword id="11894310" type="UNKNOWN" weightage="60" keywordseo="vaccine" source="Orion">vaccine</keyword>.</li></ul>The world may need new COVID-19 vaccines by mid-2022 to protect against coronavirus mutations, BioNTech CEO <a href="https://www.businessinsider.com/pzifer-fda-coronavirus-vaccine-covid-19-vaccinated-biotech-biotechnology-2020-11?r=US&amp;IR=TIR=T">Ugur Sahin</a> told the <a href="https://www.ft.com/content/d88457da-6bbc-4f07-82a6-4738aa845492">Financial Times</a> on Sunday.Sahin told the publication that current <a href="https://www.businessinsider.com/covid-vaccines-compared-vaccine-pfizer-oxford-moderna-astrazeneca-side-effects-2021-2?r=US&amp;IR=TIR=T">COVID-19 vaccines</a>, including the one BioNTech developed with Pfizer,<a href="https://www.businessinsider.com/delta-variant-covid-vaccine-effectiveness-protection-pfizer-moderna-astrazeneca-2021-7"> worked against circulating variants</a>, such as the <a href="https://www.businessinsider.com/delta-variant-covid-good-news-vaccines-still-work-pfizer-mandate-2021-9?r=US&amp;IR=TIR=T">highly contagious Delta variant</a>, and that <a href="https://www.businessinsider.com/booster-shot-walgreens-pfizer-side-effects-2021-9">booster shots</a> could give further protection.But future variants of the <keyword id="12241888" type="UNKNOWN" weightage="60" keywordseo="virus" source="Orion">virus</keyword> could evade the immune response these vaccines produce, Sahin told the Financial Times."Tailored" COVID-19 vaccines could therefore be needed, he said."This year [a different vaccine] is completely unneeded. But by mid next year, it could be a different situation," Sahin said."This virus will stay, and the virus will further adapt," Sahin told the FT. "We have no reason to assume that the next generation virus will be easier to handle for the immune system than the existing generation. This is a continuous evolution, and that evolution has just started."<keyword id="11894069" type="UNKNOWN" weightage="60" keywordseo="vaccination" source="Orion">Vaccination</keyword> programs around the world will have two separate focuses next year: one for vaccinated people needing <a href="https://www.businessinsider.com/list-country-vaccine-rate-below-world-health-organization-target-september-2021-9">booster shots</a>, and another for unvaccinated people with less access to shots, Sahin said.<a href="https://www.businessinsider.com/pfizer-ceo-normal-life-within-a-year-2021-9">Pfizer CEO Albert Bourla said</a> in late September on ABC <keyword id="11893589" type="UNKNOWN" weightage="60" keywordseo="news" source="Orion">News</keyword>' "This Week" that life would return to normal within the next year, despite new COVID-19 variants continuing to emerge.

BioNTech's CEO says the world might need new COVID-19 vaccines by mid-2022 to protect against emerging variants

<ul><li>Pfizer’s COVID-19 vaccine is over 90% effective, data from phase III trials show. </li><li>Eli Lilly receives approval from the US FDA for its COVID-19 antibody drug for use during emergency treatment. </li><li>Brazilian health regulator has suspended clinical trials of China’s Sinovac COVID-19 vaccine, citing an "adverse incident" involving a volunteer recipient. </li></ul>After registering over 48 million COVID-19 infections, the World Health Organisation is <a href="https://www.livemint.com/science/health/who-expects-to-see-covid-19-vaccine-by-end-of-2020-at-earliest-11602548070399.html">finally expecting</a> a COVID-19 vaccine by the end of 2020 or early 2021. It takes a decade or two to design, test, and launch an effective vaccine that can protect billions of people from diseases. However, COVID-19 has forced researchers to fast-track the vaccine making process. Here’s a look at COVID-19 vaccine updates from around the world — Pfizer’s COVID vaccine is 90% effective The latest data from t<a href="https://www.businessinsider.in/science/health/news/pfizers-covid-19-vaccine-is-90-effective-in-preventing-coronavirus-in-those-who-havent-been-infected-ever-before/articleshow/79130097.cms">he US pharmaceutical giant Pfizer</a> and German biotech firm BioNTech late-stage vaccine trial shows that their COVID-19 vaccine is <a href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against">90% more effective</a> in preventing infection if a person has never come in contact with it before. This means that those who get the vaccine will be protected within 28 days of the first dose — and there is only a two-dose schedule. Eli Lilly gets USFDA nod for COVID antibody drug in emergency use The US Food and Drug Administration (USFDA) on Monday has granted emergency approval to a synthetic <a href="https://www.bloombergquint.com/onweb/eli-lilly-covid-19-antibody-therapy-gets-emergency-fda-clearance">antibody treatment against COVID-19 developed by Eli Lilly</a>. The drug was shown to reduce the risk of hospitalization and emergency room visits. The drug, Bamlanivimab, is the first major drug to be approved that was designed specifically against the coronavirus. Brazil suspends trial of Chinese COVID vaccine The Brazilian health regulator Anvisa on Monday suspended <a href="https://www.channelnewsasia.com/news/world/brazil-china-sinovac-covid-19-vaccine-trial-adverse-effect-13506350">clinical trials of China’s Sinovac COVID-19 vaccine</a>, citing an "adverse incident" involving a volunteer recipient. Anvisa in a statement referred to the "incident" that occurred on October 29 and did not reveal any further information. Argentina is looking to have access to COVID vaccine by December Argentina is looking to have possession of a COVID vaccine by December. The government said it would first administer it to the most vulnerable section of the population in the country. "We are making progress in signing the contractual agreements to make it so," the chief of the cabinet of ministers, Santiago Cafiero said on Saturday, confirming that the government wants "to have commercial agreements with countries, like Russia, or with laboratories, like Pfizer and AstraZeneca." Bharat Biotech likely to launch Covaxin in February According to a <a href="https://in.reuters.com/article/health-coronavirus-india-vaccine/exclusive-india-made-covid-19-vaccine-could-be-launched-as-early-as-february-government-scientist-idINKBN27L0WU">Reuters report</a>, Bharat Biotech COVAXIN could be launched as early as February - months earlier than expected - as last-stage trials begin this month and studies have so far shown it is safe and effective. Bharat Biotech, which is developing COVAXIN with the government-run Indian Council of Medical Research (ICMR), had earlier hoped to launch it only in the second quarter of next year. Astrazeneca is likely to begin COVID-19 vaccine trials in China AstraZeneca <a href="https://www.reuters.com/article/health-coronavirus-astrazeneca-china-idUSKBN27M0F9?taid=5fa503af260cc00001474375&amp;utm_campaign=trueAnthem:+Trending+Content&amp;utm_medium=trueAnthem&amp;utm_source=twitter">plans to start early and mid-stage clinical trials of its COVID-19 vaccine candidate in China </a>this year, a senior executive told Reuters. The vaccine trials are in its final stage in the US, UK, and other countries. AstraZeneca is developing this along with the University of Oxford, and it hopes to find data of its effectiveness from the late-stage trials by the end of this year. Adar Poonawalla says Oxford vaccine trial results likely next month The chief executive <a href="https://www.timesnownews.com/health/article/adar-poonawalla-says-india-may-get-a-covid-19-vaccine-by-jan-oxford-trial-results-likely-next-month/677545">officer of Serum Institute of India, Adar Poonawalla</a>, said that a safe and effective vaccine against the novel coronavirus might be available in the country by January next year. The Pune-based firm, which is testing and manufacturing Oxford’s Covishield vaccine in India, said if trials succeed and approvals from regulatory bodies are in place, the vaccine will be ready in time. Brazilian health regulator allows Johnson &amp; Johnson to resume trials In another development, the Brazilian health regulator Anvisa has approved the resumption of human clinical trials for Johnson &amp; Johnson’s COVID-19 vaccine. The J&amp;J vaccine is one of the four being tested in Brazil — which has the world’s third-worst outbreak behind the United States and India. CanSino Biologics delivers Covid-19 vaccine to Mexico for a late-stage trial Mexico has <a href="https://www.reuters.com/article/health-coronavirus-mexico-vaccine-idUSKBN27J21V">received </a>the first doses of a COVID-19 vaccine from Chinese pharmaceutical company CanSino Biologics Inc. for a late stage-trial on between 10,000 and 15,000 volunteers. Germany CureVac's vaccine triggers an immune response On Monday, German vaccine maker CureVac said that interim results from early trials showed that its investigational Covid-19 vaccine candidate, CvnCoV, appeared safe and triggered immune response among volunteers. "We are very encouraged by the interim Phase 1 data. It represents a critical milestone in our Covid-19 vaccine programme and strongly supports the advancement of our vaccine candidate," Franz-Werner Haas, Chief Executive Officer of CureVac, said in a statement. Aspen Pharmacare, Johnson &amp; Johnson announce a deal to make Covid-19 vaccine South African pharmaceutical giant Aspen Pharmacare signed a pact with Johnson &amp; Johnson to manufacture its Covid-19 vaccine if approved in South Africa and internationally. In a statement, Aspen said that if ongoing trials bring international health authorities to endorse the J&amp;J vaccine as effective and safe, it would be produced at Aspen's manufacturing facility in Port Elizabeth in South Africa's Eastern Cape province. Moderna prepares for the global launch of COVID-19 vaccine American biotechnology company Moderna announced that it was preparing for the global launch of its Covid-19 vaccine candidate. "We are actively preparing for the launch of mRNA-1273 and we have signed a number of supply agreements with governments around the world," Xinhua news agency quoted Moderna CEO Stephane Bancel as saying in a statement on Thursday. In addition to the Phase 3 study of the Covid-19 vaccine mRNA-1273, which is fully enrolled, Moderna now has four programs in Phase 2 studies, according to Bancel. Israel begins human trials of COVID vaccine Israel has begun <a href="https://www.businessinsider.in/science/health/news/israel-begins-human-trials-on-covid-19-vaccine/articleshow/78991044.cms?upcache=2">human trials</a> of a COVID-19 vaccine on November 1, authorities have said. Two volunteers have received the vaccine. Israel will first test the vaccine on 80 people, before extending it to 980 in the second phase, and then 25,000 in the final stage, slated for April or May. "We can see the light at the end of the tunnel," Prime Minister Benjamin Netanyahu told reporters at Sheba Medical Center near Tel Aviv. Japan’s Shionogi is planning to conduct clinical trials of COVID-19 vaccine in December Japan’s Shionogi is planning to conduct phase I clinical trials of its COVID-19 vaccine candidate in December and phase II trials in January. Moreover, Shionogi S phase III trials are likely to be done overseas “due to the relative lack of COVID-19 cases in Japan”, reported Reuters. Brazil says it might get a COVID-19 vaccine by June 2021 Brazil is expected to have a COVID-19 vaccine <a href="https://zeenews.india.com/world/brazil-will-have-a-covid-19-vaccine-by-june-2021-says-regulator-2321092.html">ready </a>by June next year, according to the head of Brazil’s health regulator Anvisa, Antonio Barra Torres. According to Reuters, Anvisa is yet to decide on the minimum efficacy required to give vaccine approval. However, the agency has approved the vaccine with less than 50% effectiveness previously. Brazil has played a significant role in conducting late-stage clinical trials of many global vaccine candidates including Oxford-AstraZeneca. Oxford-AstraZeneca’s COVID-19 vaccine triggers an immune response in both young and old adults Oxford-AstraZeneca’s COVID-19 vaccine candidate has <a href="https://in.reuters.com/article/health-coronavirus-astrazeneca-vaccine-i/oxford-covid-19-vaccine-prompts-immune-response-among-adults-old-and-young-astrazeneca-says-idUSKBN27B0L7">prompted </a>an immune response in both young and old adults. According to AstraZeneca, the vaccine also produces ‘lower adverse responses among elderly,” reported Reuters. “It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the COVID-19 disease severity is higher,” an AstraZeneca spokesman said. SEE ALSO: <a href="https://www.businessinsider.in/science/health/news/pfizers-covid-19-vaccine-is-90-effective-in-preventing-coronavirus-in-those-who-havent-been-infected-ever-before/articleshow/79130097.cms" data-type="tilCustomLink">Pfizer’s COVID-19 vaccine is 90% effective in preventing coronavirus in those who haven’t been infected ever before, shows data from latest trials</a> <a href="https://www.businessinsider.in/business/auto/news/mm-q2-earnings-tomorrow-profit-likely-to-fall-19-percent-but-tractor-sales-may-help-revenue/articleshow/79129620.cms" data-type="tilCustomLink">Strong tractor sales may cushion M&amp;M’s revenue but profit is likely to remain under pressure, say analysts</a>

COVID-19 vaccine tracker: Pfizer says COVID-19 vaccine over 90% effective, Eli Lilly’s antibody drug therapy gets FDA nod for emergency use, Brazil suspends trial of Chinese coronavirus vaccine

<ul class="summary-list"><li><keyword id="11897118" type="UNKNOWN" weightage="60" keywordseo="pfizer" source="Orion">Pfizer</keyword> could have helped low-income countries better distribute <keyword id="11893994" type="UNKNOWN" weightage="60" keywordseo="covid-19" source="Orion">COVID-19</keyword> vaccines, the CEO said.</li><li>CEO <keyword id="6924082" type="UNKNOWN" weightage="60" keywordseo="albert-bourla" source="Orion">Albert Bourla</keyword> said he should have helped improve vaccine-distribution infrastructure.</li></ul>Pfizer CEO Albert Bourla acknowledged the pharmaceutical giant could have worked better to ensure low-income countries got enough COVID-19 vaccines.Bourla said low-income countries have asked Pfizer to stop sending additional doses because they "cannot process them," or the countries <a href="https://www.businessinsider.com/jen-psaki-says-south-africa-turned-down-us-offer-of-more-vaccine-doses-2021-11">lack infrastructure</a> to distribute many shots at once. In retrospect, Bourla said he would have worked with governments and nonprofits in low-income countries well in advance to ensure they had the infrastructure to distribute doses. "We are using drones to drop vaccine supplies in remote areas," Bourla said during the Wall Street Journal's CEO Council Summit on Tuesday. "We should have done it better, many other organizations should have done it better."Though more than half of the world's population has received at least one dose of a <keyword id="11896806" type="UNKNOWN" weightage="60" keywordseo="covid-19-vaccine" source="Orion">COVID-19 vaccine</keyword>, just 6.3% of people in low-income countries have received a shot, according to <a href="https://ourworldindata.org/covid-vaccinations">Our World in Data</a>, a research project from Oxford University.As poor nations lack vaccines, some rich countries are scrambling to get rid of their surplus. This summer, <a href="https://www.businessinsider.com/rich-countries-excess-vaccines-scramble-get-rid-expire-2021-7">Israel was on the cusp of throwing away</a> hundreds of thousands of doses set to expire before donating them to South Korea. The World Health Organization is asking wealthier nations to <a href="https://www.businessinsider.com/who-warn-stop-hoard-vaccine-3rd-dose-some-countries-none-2021-7">prioritize sending vaccines to other nations</a> instead of bolstering booster shot campaigns. The Centers for Disease Control and Prevention recently recommended all US adults get <a href="https://www.businessinsider.com/cdc-over-50-get-boosters-now-younger-adults-decide-2021-11">a COVID-19 booster</a> once eligible. Bourla touted Pfizer's decision to sell vaccines at a higher price to rich countries and at low or no cost to less wealthy ones. The company, he added, ramped up manufacturing to ensure they could produce vaccines <a href="https://www.businessinsider.com/pfizer-will-meet-covid-vaccine-dose-goal-early-ceo-said-2021-4">quicker than they had predicted</a>.Bourla said vaccinating the global population will inhibit the virus from mutating into variants, and help society return to a relatively normal life. "Once we get people vaccinated, once we get the politics out of the equation...we can live normal lives," he told the WSJ's Jamie Heller.<a href="https://www.statnews.com/pharmalot/2020/05/28/who-voluntary-pool-patents-pfizer/">Pfizer</a>, along with other major pharmaceutical companies, has opposed a ruling that would remove protections on the company's intellectual property of the COVID-19 vaccine.Former world leaders, including 100 Nobel laureates, penned a letter to President Joe Biden asking him to <a href="https://www.businessinsider.com/former-world-leaders-urge-biden-suspend-covid-19-vaccine-patents-2021-4">suspend vaccine patents</a>. The move would enable manufacturers in poorer nations to make Pfizer or Moderna's vaccine without fear of reprisal.

Pfizer should have helped low-income countries better distribute COVID-19 vaccines, CEO said

<ul class="summary-list"><li>One dose of <keyword id="44612" type="CITY" weightage="60" keywordseo="Pfizer">Pfizer</keyword> or <keyword id="6409874" type="COMPANY" weightage="60" keywordseo="astrazeneca">AstraZeneca</keyword> vaccines was more than 86% effective at preventing COVID-19, data shows.</li><li>South Korean <keyword id="6354750" type="UNKNOWN" weightage="60" keywordseo="health">health</keyword> officials <a href="https://twitter.com/KoreaDCA/status/1389461942213824515" target="_blank" rel="noopener">said Tuesday</a> that more than 520,000 Koreans over 60 had had a single shot.</li><li>The data from <keyword id="5565" type="COUNTRY" weightage="60" keywordseo="South-Korea">South Korea</keyword> didn't show how long protection lasts.</li></ul>A <a href="https://www.businessinsider.com/covid-vaccine-one-shot-effectiveness-pfizer-moderna-astrazeneca-vaccines-dose-2021-3" target="_blank" rel="noopener">single dose of Pfizer or AstraZeneca's COVID-19 vaccines</a> was more than 86% effective at stopping <keyword id="1754604" type="PERSON" weightage="60" keywordseo="coronavirus">coronavirus</keyword> in older people at least two weeks after vaccination, real-world data from South Korea shows.Both vaccines are authorized to be given as two injections, spaced weeks apart, but this data again shows that they offer some protection between doses.The Korea Disease Control and Prevention Agency (KDCA) <a href="https://twitter.com/KoreaDCA/status/1389461942213824515">said on Twitter Tuesday</a> that one dose of the <keyword id="24209" type="PERSON" weightage="60" keywordseo="vaccine">vaccine</keyword> co-developed by Pfizer and <keyword id="3124139" type="PERSON" weightage="60" keywordseo="BioNTech">BioNTech</keyword> was 89.7% effective at preventing COVID-19 in South Koreans aged over 60. The vaccine co-developed by AstraZeneca and <keyword id="30725" type="ORGANIZATION" weightage="60" keywordseo="Oxford-university">Oxford University</keyword> was 86% effective at preventing COVID-19 after one dose, it said.The KDCA analysis included more than 520,000 people who had been vaccinated with a single dose of either vaccine.In the data collected, 1,237 COVID-19 cases were reported, and only 29 came from the vaccinated group, <a href="https://www.reuters.com/world/asia-pacific/skorea-says-astrazeneca-pfizer-covid-19-vaccines-87-effective-after-first-shot-2021-05-05/">the KDCA said in a press release</a>.The agency didn't provide a breakdown of how many people received each shot or the severity of illness - COVID-19 vaccines are generally more effective at preventing COVID-19 infections that cause hospitalization or death.The KDCA said the vaccines' protective effect was higher when the second vaccination was completed, so a second shot within the recommended period was "absolutely necessary".Read more: <a href="https://www.businessinsider.com/pfizers-coronavirus-vaccine-2021-timeline-for-children-trials-2021-5" target="_blank" rel="noopener">One slide lays out Pfizer's busy 2021 plans for its COVID-19 vaccine, including when it could start being used in kids</a> South Korea's findings adds to a growing body of real-world data suggesting that a single shot of a COVID-19 vaccine protects against COVID-19, but it's still not clear how long protection from a single dose may last.<a href="https://www.businessinsider.com/one-dose-astrazeneca-or-pfizer-vaccine-protects-against-covid-19-2021-4">Real-world data from the UK</a>, posted as a <a href="https://www.businessinsider.com/one-dose-astrazeneca-or-pfizer-vaccine-protects-against-covid-19-2021-4">pre-print study on April 23</a>, found that either Pfizer or AstraZeneca's vaccine cut COVID-19 infections with symptoms by 72%. Protection from a single dose probably holds up for at least 10 weeks, based on measurements of antibody levels, the study, which wasn't peer-reviewed, said.Another real-world study from Scotland <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00677-2/fulltext?utm_campaign=lancetcovid21&amp;utm_content=163707807&amp;utm_medium=social&amp;utm_source=twitter&amp;hss_channel=tw-27013292nnel=tw-27013292">published in the Lancet</a> on April 23 found that a single dose of Pfizer's vaccine was 91% effective against hospitalization at 28 to 34 days following vaccination. One dose of AstraZeneca's vaccine was 88% effective against hospital admissions after the same time period, the study found.

One dose of Pfizer or AstraZeneca vaccine was highly effective at preventing coronavirus in older people, real-world data from South Korea suggests

New York, Pfizer-BioNtech's Covid-19 vaccine offers at least 97 per cent effectiveness in symptomatic Covid-19 cases, according to real world data published by the pharma company. The analysis, based on real world data gathered by the Israel Ministry of Health, also found the vaccine's effectiveness at 94 per cent against asymptomatic SARS-CoV-2 infections. "We are extremely encouraged that the real-world effectiveness data coming from Israel are confirming the high efficacy demonstrated in our Phase 3 clinical trial and showing the significant impact of the vaccine in preventing severe disease and deaths due to Covid-19," Luis Jodar, Senior Vice President and Chief Medical Officer, <keyword id="44612" type="CITY" weightage="20" keywordseo="Pfizer">Pfizer</keyword> Vaccines, said in a statement. The latest data analysis finds unvaccinated individuals were 44 times more likely to develop symptomatic Covid-19 and 29 times more likely to die from this virus-borne disease. This comprehensive real-world evidence can be of importance to countries around the world as they advance their own vaccination campaigns one year after the <keyword id="43588" type="COMPANY" weightage="20" keywordseo="World-Health-Organization">World Health Organization</keyword> (WHO) declared Covid-19 a pandemic, the statement said. In January, Pfizer and the Israel MoH entered into a collaboration agreement to monitor the real-world impact of the Pfizer-BioNTech Covid-19 vaccine. The findings from the analysis were derived from de-identified aggregate Israel MoH surveillance data collected between January 17 and March 6, 2021. For all outcomes, vaccine effectiveness was measured from two weeks after the second dose.

Pfizer vaccine 97% effective in symptomatic Covid 19 cases: Study

<ul><li>The US, UK, European Union, India and other countries are currently mulling over the approval of COVID-19 vaccines for the masses amid growing concerns over allergic reactions.</li><li>Data shows that more than 1.9 million people in the US have received a Pfizer and Moderna’s COVID-19 vaccine dose, but only ten cases of anaphylaxis are under investigation. </li><li>Only one case of anaphylaxis has been reported after receiving Moderna’s COVID-19 vaccine. </li></ul>More than 1.9 million people in the US have gotten a COVID-19 vaccine dose, and the European Union (EU) has put its program to vaccinate 450 million across the continent into gear. <div type="Article" hostid="261" msid="79989056" title="COVID-19 vaccination campaign begins in Germany, Greece, Sweden, and other European nations" mstype="2" mssubtype="0"></div> In the US, all eyes are on Pfizer and Moderna. Meanwhile, in the UK, the Pfizer vaccine has been administered to more than 600,000 citizens. All eyes are on the Oxford-AstraZeneca COVID-19 vaccine’s pending approval. As countries rush to make the vaccine available, there are growing concerns around the reported adverse allergic reactions. Allergic reactions to Pfizer’s COVID-19 vaccine Pfizer and BioNTech’s COVID-19 vaccine was the first to roll out. It also has the most reports of severe allergic reactions compared to the only other vaccine which has approval so far, Moderna. Federal agencies in the US <a href="https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/index.html">are investigating</a> at least ten cases of people who suffered anaphylaxis — a severe allergic reaction — after receiving Pfizer’s vaccine. In Alaska, two cases reported tongue swelling, hoarse voice and difficulty breathing within ten minutes of taking the first dose. At least two health care workers in Britain have also experienced severe allergic reactions after receiving the Pfizer vaccine earlier this month. They are understood to have suffered an ‘anaphylactoid’ reaction, which involves skin rashes, breathlessness and sometimes a drop in blood pressure. This is different from anaphylaxis reactions, which can be fatal if immediate medical aid isn’t administered. The UK has advised that anyone with a history of anaphylaxis to medicine or food shouldn’t get the vaccine. Food and Drug Administration (FDA) and the Center for Disease Control and Prevention (CDCP) officials have discussed some cases. Still, they have not determined whether an ingredient in the vaccine caused allergic responses. However, some <a href="https://www.wsj.com/articles/scientists-eye-potential-culprit-for-covid-19-vaccine-allergic-reactions-11608901200">researchers believe</a> that polyethylene glycol (PEG) could be responsible. Allergic reactions to Moderna’s COVID-19 vaccine The first case of an extreme adverse side-effect to Moderna’s COVID-19 vaccine was reported last week. A doctor in Boston said he developed a severe allergic reaction to the vaccine within minutes of administration. He has a prior history of being allergic to shellfish. David Kibbe, the spokesman for Boston Medical Centre, confirmed the allergic reaction. “He was taken to the Emergency Department, evaluated, treated, observed and discharged. He is doing well today” Kibbe said in a statement. Moderna’s spokesman, Ray Jordan, communicated that the company will not comment on individual cases but that the company’s medical safety team is looking into the issue. To battle the overload of misinformation around the COVID-19 pandemic and the upcoming vaccine, the CDC will be launching a <a href="https://covid.cdc.gov/covid-data-tracker/#vaccinations">new portal on the agency website</a> with information on reactions to COVID-19 vaccines starting this week. SEE ALSO: <a href="https://www.businessinsider.in/science/space/news/indian-space-startup-skyroot-aerospace-successfully-test-fires-first-solid-rocket-propulsion-stage-demonstrator-called-kalam-5/articleshow/79988975.cms">India’s first-ever privately designed and developed rocket is a step closer to becoming a reality in 2021</a> <a href="https://www.businessinsider.in/business/corporates/news/jack-ma-ant-group-asked-to-overhaul-its-business-model-by-china-central-bank/articleshow/79987683.cms">China's central bank wants Jack Ma's Ant Group to overhaul its business model</a> <a href="https://www.businessinsider.in/science/environment/news/top-10-most-expensive-natural-disasters-of-2020-in-the-world/slidelist/79986294.cms">Cyclone Amphan was the most expensive cyclone of 2020 and the fourth most expensive natural disaster overall</a>

COVID-19 vaccines and their extreme allergic reactions are far and few between — these are some of the side effects to watch out for

Washington, Nearly a quarter of the world's population may not have access to a <keyword id="8904563" type="UNKNOWN" weightage="20" keywordseo="covid-19-vaccine">COVID-19 vaccine</keyword> until at least 2022, according to a study published in The BMJ on Wednesday which warns that vaccines will be as challenging to deliver as they were to develop. Another study in the same journal estimates that 3.7 billion adults worldwide are willing to have a COVID-19 vaccine, highlighting the importance of designing fair and equitable strategies to ensure that supply can meet demand, especially in low and <keyword id="1226877" type="PERSON" weightage="20" keywordseo="middle-income-countries">middle income countries</keyword>. These findings together suggest that the operational challenges of the global COVID-19 vaccination programme will be at least as difficult as the scientific challenges associated with their development. In the first study, researchers from the Johns Hopkins Bloomberg School of Public Health in the US analysed pre-orders for COVID-19 vaccines ahead of their regulatory approval that had been publicly announced by countries around the world. "This study provides an overview of how high income countries have secured future supplies of COVID-19 vaccines, but that access for the rest of the world is uncertain," the researchers said. "Governments and <keyword id="59868" type="ORGANIZATION" weightage="20" keywordseo="Manufacturers">manufacturers</keyword> might provide much needed assurances for equitable allocation of COVID-19 vaccines through greater transparency and accountability over these arrangements," they said. The researchers noted that by November 15, 2020, several countries had reserved a total of 7.48 billion doses, or 3.76 billion courses from 13 manufacturers, out of 48 COVID-19 vaccine candidates in clinical trials. They said over half (51%) of these doses will go to high income countries, which represent 14% of the world's population, while low and middle income countries will potentially have the remainder, despite these comprising more than 85% of the world's population. If all of these vaccine candidates were successfully scaled, the total projected manufacturing capacity would be 5.96 billion courses by the end of 2021, with prices ranging from USD 6 per course to as high as USD 74 per course. Up to 40% of the vaccine courses from these manufacturers might potentially remain for low- and middle-income countries, the researchers said. However, this will depend, in part, on how high-income countries share what they procure and whether the US and Russia participate in globally coordinated efforts, they said. The researchers noted that even if all of these vaccine manufacturers were to succeed in reaching their <keyword id="10441850" type="UNKNOWN" weightage="20" keywordseo="maximum-production-capacity">maximum production capacity</keyword>, at least a fifth of the world's population would not have access to vaccines until 2022. In the second study, researchers in China and the US estimated target populations for whom vaccines would be required, to help guide development of fair and equitable allocation strategies across the globe. They found that target population sizes for COVID-19 vaccination vary widely by <keyword id="10441849" type="UNKNOWN" weightage="20" keywordseo="geographical-region">geographical region</keyword>, vaccine objectives, such as maintaining essential core services, reducing severe COVID-19, and stopping virus transmission, and the impact of vaccine hesitancy in reducing demand. The researchers point to evidence suggesting that around 68% of the global population (3.7 billion adults) is willing to receive a COVID-19 vaccine, and say their findings "provide an evidence base for global, regional, and national vaccine prioritisation and allocation." "Variations in the size of the target populations within and between regions emphasise the tenuous balance between vaccine demand and supply, especially in low and middle income countries without sufficient capacity to meet domestic demand for COVID-19 vaccine" they said. Both studies are observational, and the researchers acknowledge the implications of uncertainty and incomplete information for their analyses. The findings illustrate the considerable scale and complexity of manufacturing, purchasing, distributing, and administering COVID-19 vaccines in a way that meets global needs, and does so equitably among nations and populations, the researchers said. Jason Schwartz at Yale School of Public Health noted in a linked editorial that many countries have already shown a commitment to equitable global access to COVID-19 vaccines by purchasing through <keyword id="9582643" type="COMPANY" weightage="20" keywordseo="the-covax-facility">the COVAX Facility</keyword> -- an initiative that invests part of the payment in vaccines for poorer countries. However, he said vigilance is required "to ensure that such aspirations are realised in the months and years ahead." SEE ALSO: <a href="https://www.businessinsider.in/stock-market/news/top-stocks-to-watch-idbi-bank-pnb-bank-axis-bank-mm-embassy-reit-pvr-and-others/articleshow/79750662.cms">Top stocks to watch — IDBI Bank, PNB Bank, Axis Bank, M&amp;M, Embassy REIT, PVR, and others</a> <a href="https://www.businessinsider.in/defense/news/india-inaugurates-new-railway-line-with-bangladesh-to-save-its-chickens-neck-from-china-on-vijay-diwas/articleshow/79750869.cms">After 55 years, India will inaugurate a new railway line with Bangladesh to save its ‘Chicken’s Neck’ from China</a> <a href="https://www.businessinsider.in/finance/news/gold-loan-providers-in-india-face-a-rise-in-robberies-as-gold-prices-rise/articleshow/79752387.cms">Gold loan providers in India face a rise in robberies as gold prices rise</a>

Nearly a quarter of the world's population may not have access to the COVID-19 vaccine until 2022, BMJ study shows

<ul><li>Astrazeneca and Oxford University have acknowledged a manufacturing error that is raising questions about preliminary results of their experimental COVID-19 vaccine.</li><li>Bharat Biotech’s COVID-19 vaccine candidate, Covaxin, will begin its phase III trials at the Sola civil hospital in Ahmedabad, Gujarat.</li><li>Pfizer begins process to register its COVID-19 vaccine in Brazil.</li></ul>The latest wave of COVID-19 infections across the world has taken the global tally of cases over the 60 million mark. Deaths in the US have surpassed 2,60,000, a new grim milestone amid an unabated resurgence in the worst hit country in the world, according to Johns Hopkins University. India stands second with over 92 lakh cases. Here’s a look at COVID-19 vaccine updates from around the world — Astrazeneca admits manufacturing ‘error’ in vaccine AstraZeneca and Oxford University have acknowledged a manufacturing error that is raising questions about preliminary results of their experimental COVID-19 vaccine. A statement describing the error on November 25 comes days after the company and the university described the shots as "highly effective" and made no mention of why some study participants didn't receive as much vaccine in the first of two shots as expected. The group of volunteers that got a lower dose seemed to be much better protected than the volunteers who got two full doses. Astrazeneca said that in the low-dose group, the vaccine appeared to be 90%effective. Whereas the group that got two full doses, the vaccine appeared to be 62% effective. The drugmakers said that combined, the vaccine appeared to be 70% effective. Covaxin reaches Gujarat for phase III trials Bharat Biotech’s COVID-19 vaccine candidate, Covaxin, will begin its phase III trials at the Sola civil hospital in Ahmedabad, Gujarat. The hospital has received 500 doses of the vaccine candidate for the trial, Gujarat deputy CM Nitin Patel said. The vaccine will be tested on healthy and elderly volunteers and health workers. They will receive two doses of the potential vaccine per month during this trial. Covaxin is being developed by the Hyderabad-based firm in collaboration with the Indian Council of Medical Research (ICMR). Pfizer begins process to register its COVID-19 vaccine in Brazil Pfizer has started the process to register its COVID-19 vaccine in Brazil. It has submitted the results of its tests to the country’s health regulators. "This is an important step so that the vaccine can be available in Brazil," Pfizer said in a <a href="https://www.barrons.com/news/in-brazil-pfizer-begins-process-to-register-covid-19-vaccine-01606353006">statement</a>. Pfizer’s COVID-19 vaccine candidate is being developed in collaboration with the German pharmaceutical BioNTech. Sinopharm applies for license to bring its vaccine to the market for public use Sinopharm’s subsidiary, China National Biotec Group, has applied to the country’s health regulators to bring its COVID-19 vaccine candidate to the market for public use, according to <a href="https://news.cgtn.com/news/2020-11-25/Sinopharm-applies-to-bring-its-COVID-19-vaccine-to-market--VIiimRueZy/index.html">reports</a>. The application may include data from the company’s phase III trials conducted in the Middle East and South America. However, the company has not made the results of the vaccine's efficacy public yet. (with inputs from agencies) SEE ALSO: <a href="https://www.businessinsider.in/stock-market/news/us-stocks-dip-from-record-levels-on-disappointing-economic-data-and-soaring-covid-19-cases/articleshow/79418413.cms" data-type="tilCustomLink">US stocks dip from record levels on disappointing economic data and soaring COVID-19 cases</a> <a href="https://www.businessinsider.in/sports/news/diego-maradona-one-of-the-greatest-stars-in-soccer-history-has-died-at-the-age-of-60/articleshow/79414628.cms" data-type="tilCustomLink">Diego Maradona, one of the greatest stars in soccer history, has died at the age of 60</a>

COVID-19 vaccine latest updates: Astrazeneca’s manufacturing ‘error’ raises concerns on vaccine efficacy, Covaxin to begin phase III trials in Gujarat

<ul class="summary-list"><li>Russian President <keyword id="43440" type="PERSON" weightage="60" keywordseo="Vladimir-Putin">Vladimir Putin</keyword> announced that he wants tourists to visit <keyword id="6358826" type="LOCATION" weightage="60" keywordseo="Russia">Russia</keyword> to get the new <keyword id="9739267" type="UNKNOWN" weightage="60" keywordseo="Sputnik-V">Sputnik V</keyword> <keyword id="8904563" type="UNKNOWN" weightage="60" keywordseo="covid-19-vaccine">COVID-19 vaccine</keyword>.</li><li>The Sputnik V is still under review by the World Health Organization and European Medicines Agency.</li><li>Russia is currently reporting nearly 9,000 new <keyword id="8763838" type="UNKNOWN" weightage="60" keywordseo="covid-19">COVID-19</keyword> cases per day.</li></ul>Russian President Vladimir Putin wants to encourage "vaccine tourism," where foreign citizens can visit the country to get a free Sputnik V COVID-19 vaccine."There is widespread practice where business people and heads of companies come specifically to Russia to get a jab against the <keyword id="1754604" type="PERSON" weightage="60" keywordseo="coronavirus">coronavirus</keyword>," Putin told the St. Petersburg <keyword id="6356001" type="UNKNOWN" weightage="100" keywordseo="international">International</keyword> Economic Forum, <a href="https://www.themoscowtimes.com/2021/06/04/putin-wants-vaccine-tourism-plan-by-end-june-a74117">the Moscow Times reported.</a>He added that he wanted "to be able to organize the conditions for foreign citizens to come to Russia and get vaccinated on a commercial basis."The Russian Direct Investment Fund, the organization that's promoting Sputnik V COVID-19 vaccine, <a href="https://twitter.com/sputnikvaccine/status/1400758614063828995">said on Twitter on Friday</a> that vaccine tourism would launch by July.The country is advocating for the Sputnik V, but the vaccine is <a href="https://www.themoscowtimes.com/2021/06/03/who-europe-medicines-agency-finishing-sputnik-v-review-reports-a74096">still under review</a> by the World Health Organization and the European Medicines Agency. Unlike the Moderna and Pfizer "MRNA vaccines" that are popular in the US, the Sputnik V is a <a href="https://www.dw.com/en/is-sputnik-v-vaccine-safe/a-57219314">"viral vector vaccine"</a> akin to the AstraZeneca and Johnson &amp; Johnson COVID-19 vaccines.According to the <a href="https://www.themoscowtimes.com/2021/06/04/coronavirus-in-russia-the-latest-news-june-4-a69117">Moscow Times</a>' COVID-19 case tracker, Russia is currently reporting around 9,000 new COVID-19 cases per day.

You Searched For "covid 19 vaccine for world" and got 11 results

Russia claims its new COVID-19 vaccine has pre-orders from 20 countries

BI India Bureau

BioNTech's CEO says the world might need new COVID-19 vaccines by mid-2022 to protect against emerging variants

Kate Duffy

COVID-19 vaccine tracker: Pfizer says COVID-19 vaccine over 90% effective, Eli Lilly’s antibody drug therapy gets FDA nod for emergency use, Brazil suspends trial of Chinese coronavirus vaccine

BI India Bureau

Pfizer should have helped low-income countries better distribute COVID-19 vaccines, CEO said

Allana Akhtar

One dose of Pfizer or AstraZeneca vaccine was highly effective at preventing coronavirus in older people, real-world data from South Korea suggests

Dr. Catherine Schuster-Bruce

Pfizer vaccine 97% effective in symptomatic Covid 19 cases: Study

IANS

COVID-19 vaccines and their extreme allergic reactions are far and few between — these are some of the side effects to watch out for

BI India Bureau

Nearly a quarter of the world's population may not have access to the COVID-19 vaccine until 2022, BMJ study shows

PTI

COVID-19 vaccine latest updates: Astrazeneca’s manufacturing ‘error’ raises concerns on vaccine efficacy, Covaxin to begin phase III trials in Gujarat

BI India Bureau

Putin wants to lure vaccine tourists to Russia so foreigners can get the Sputnik V COVID-19 jab

Kelly McLaughlin

Hey COVID vaccine sceptics ⁠— healthcare experts answer some of the worrying questions

Kavita Majumdar

Popular Keywords

Buying Guides